Archive
-
Working Paper
Working PaperImplications of the Inflation Reduction Act for the Biotechnology Industry
Jul 2024
Sensitivity of investment and valuation to drug price indices and market conditions
-
Working Paper
Working PaperConsidering Returns on Federal Investment in the Negotiated “Maximum Fair Price” of Drugs Under the Inflation Reduction Act: an Analysis
Mar 2024
The empirical analysis of public sector investments and the health value created by the drugs selected for Medicare price negotiations provides a cost basis for the assessment of the maximum fair price.
-
Working Paper
Working PaperWhat Next for the Post Covid Global Economy: Could Negative Supply Shocks Disrupt Other Fragile Systems?
Jan 2023
The principal threat to economic stability currently is the overhang of debt, both private and public.
-
Working Paper
Working Paper SeriesFirm-Level Exposure to Epidemic Diseases: Covid-19, SARS, and H1N1
Apr 2020
As Covid-19 spreads globally in the first quarter of 2020, this paper finds that firms’ primary concerns relate to the collapse of demand, increased uncertainty, and disruption in supply chains